Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent.

ABSTRACT: The development of an effective prophylactic hepatitis C virus (HCV) vaccine is a priority to achieve global elimination of the virus. Accurate assessment of the neutralizing breadth of antibodies induced by vaccines and a clear understanding of the antigenic differences between viral variants included in vaccines are both critical for vaccine development. Prior studies have indicated that HCV genotypes (gts) do not dictate the sensitivity of HCV envelope glycoprotein (E1E2) variants to neutralizing antibodies. However, most of these prior studies under-sampled variants from gts 2-6. Here, we selected a genetically diverse and representative panel of gt 2-6 E1E2 variants, used them to generate HCV pseudoparticles (HCVpp), and measured neutralization of these HCVpp by neutralizing antibodie

SUBMITTER: Mimms JL 

PROVIDER: S-EPMC12798819 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature